Table 1.
Characteristics of clinical, immunological, and virological parameters, and antiretroviral treatment of vertically HIV-1-infected children.
| Previous-ART | |
| N. of HIV-children | 42 |
| Age (years)(a) | 6.7 ± 0.64 (0.5; 16.1) |
| Male(b) | 16 (38.1%) |
| AIDS diagnosis (CDC)(b) | 23 (54.7%) |
| Baseline CD4+cell count | |
| % CD4+(a) | 23.2 ± 1.8 (0.8; 49.7) |
| 15 – 25% CD4+(b) | 13 (22%) |
| <15 % CD4+(b) | 16 (27.1%) |
| Baseline HIV-RNA level | |
| log10 VL (copies/mL)(a) | 4.52 ± 0.11 (3.22; 6.84) |
| VL >50,000 copies/mL(b) | 14 (33.3%) |
| ART with NRTI prior-HAART(b) | |
| Monotherapy | 39 (92.9%) |
| Therapy combined | 3 (7.1%) |
| HAART regimen at baseline(b) | |
| 3TC + d4T + NFV | 27 (64.3%) |
| AZT + 3TC + NFV | 6 (14.3%) |
| d4T + ddI + NFV | 9 (21.49%) |
| New NRTI on HAART | |
| 0 NRTI | 14 (33.3%) |
| 1 NRTI | 14 (33.3%) |
| 2 NRTI | 14 (33.3%) |
| HAART regimen during follow-up(b) | |
| Global adherence (>90%) | 100% |
| Change of drugs on first line of HAART | 9 (21.4%) |
| Change of NRTI | 2 (4.8%) |
| Adding a NNRTI | 4 (9.5%) |
| Adding a PI | 3 (7.1%) |
| Stop of HAART with NFV | 16 (38.1%) |
| Change of NFV by other PI | 12 (28.6%) |
| Interruption of HAART | 4 (9.5%) |
Values are expressed as: a) mean ± s.e.m. (min; max), and b) absolute (percentage). VL: viral load; CDC: Center for Disease Control. HAART: highly active antiretroviral therapy.